We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
- Authors
Qualls, David; Imber, Brandon S.; Okwali, Michelle; Hamlin, Paul A.; Kumar, Anita; Lahoud, Oscar B.; Matasar, Matthew J.; Noy, Ariela; Owens, Colette; Zelenetz, Andrew D.; North, Victoria S.; Schöder, Heiko; Dogan, Ahmet; Salles, Gilles; Yahalom, Joachim; Falchi, Lorenzo
- Abstract
Fifteen patients (83%) received combined modality therapy with R-CHOP followed by radiation therapy (RT); among these, 10 had short-course R-CHOP (three to four cycles) and five completed full course R-CHOP (six cycles). Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era Keywords: diffuse large B cell lymphoma; ocular adnexa; orbit; outcomes; radiation; rituximab; treatment EN diffuse large B cell lymphoma ocular adnexa orbit outcomes radiation rituximab treatment 524 527 4 02/07/23 20230215 NES 230215 Primary diffuse large B-cell lymphoma involving the ocular adnexa (OA-DLBCL), including the orbit, eyelids or lacrimal glands, is a rare manifestation of DLBCL, and data to guide management are limited.[[1], [3]] Historically OA-DLBCL has been associated with poor prognosis, but reported cases were largely treated prior to the rituximab era, and many were managed with local therapy alone without systemic chemotherapy.[[2], [4], [6]] In the rituximab era, its prognosis remains unknown, particularly in individuals with limited-stage disease.[8] Published case series of patients with extranodal limited-stage DLBCL rarely included OA-DLBCL.[9] Thus, the optimal management and outcomes of patients with limited-stage OA-DLBCL treated with modern therapy remain poorly defined.
- Subjects
ADNEXAL diseases; COMBINED modality therapy; DIFFUSE large B-cell lymphomas; POSITRON emission tomography computed tomography; RITUXIMAB; TREATMENT effectiveness
- Publication
British Journal of Haematology, 2023, Vol 200, Issue 4, p524
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18590